Newest therapeutic strategies impacting on rarest thoracic malignancies: The clinical case report of biphasic pleural mesothelioma

被引：0
作者：
Pellicioli, F. [1 ,2 ]
Sala, L. [1 ]
Colonese, F. [1 ]
Belloni, E. [3 ]
Abbate, M. I. [1 ]
Canova, S. [1 ]
D'Agostino, A. [1 ]
Cortinovis, D. L. [1 ,4 ]
机构：
[1] IRCCS San Gerardo Tintori Fdn, CS Med Oncol, Monza, Italy
[2] Univ Brescia, Dept Med Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy
[3] IRCCS San Gerardo Tintori Fdn, CS Pathol Anat, Monza, Italy
[4] Univ Milano Bicocca, Med & Surg Dept, Milan, Italy
来源：
HELIYON | 2024年 / 10卷 / 16期
关键词：
Case report; Pleural mesothelioma; Clinical trial; OPEN-LABEL; PHASE-III; PEMBROLIZUMAB; CHEMOTHERAPY; CISPLATIN;
D O I：
10.1016/j.heliyon.2024.e36306
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
A caucasian 62-year-old woman, diagnosed with biphasic pleural mesothelioma (PM) of II stage and BAP1 loss, was treated with therapies included in clinical trial and Early Access Programmes (EAP). During her clinical history, radiological images presented an unusual representation of the disease, with a pseudo progression discussed many times by several specialists. The patient's overall survival improved as a result of the multidisciplinary team and the availability of medicines outside of clinical practice.
引用
收藏
页数：5
相关论文
共 33 条
  • [1] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
    Alley, Evan W.
    Lopez, Juanita
    Santoro, Armando
    Morosky, Anne
    Saraf, Sanatan
    Piperdi, Bilal
    van Brummelen, Emilie
    [J]. LANCET ONCOLOGY, 2017, 18 (05) : 623 - 630
  • [2] Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
    Armato, Samuel G., III
    Nowak, Anna K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : 1012 - 1021
  • [3] The eighth TNM classification for malignant pleural mesothelioma
    Berzenji, Lawek
    Van Schil, Paul E.
    Carp, Laurens
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (05) : 543 - 549
  • [4] Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach
    Bilfinger, Thomas V.
    Albano, Denise
    Perwaiz, Muhammed
    Keresztes, Roger
    Nemesure, Barbara
    [J]. CLINICAL LUNG CANCER, 2018, 19 (04) : 346 - 351
  • [5] Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database
    Bou-Samra, Patrick
    Chang, Austin
    Azari, Feredun
    Kennedy, Gregory
    Segil, Alix
    Guo, Emily
    Marmarelis, Melina
    Langer, Corey
    Singhal, Sunil
    [J]. CANCER MEDICINE, 2023, 12 (11): : 12208 - 12220
  • [6] Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
    Canova, S.
    Ceresoli, G. L.
    Grosso, F.
    Zucali, P. A.
    Gelsomino, F.
    Pasello, G.
    Mencoboni, M.
    Rulli, E.
    Galli, F.
    De Simone, I.
    Carlucci, L.
    De Angelis, A.
    Belletti, M.
    Bonomi, M.
    D'Aveni, A.
    Perrino, M.
    Bono, F.
    Cortinovis, D. L.
    [J]. ESMO OPEN, 2022, 7 (06)
  • [7] BAP1 in cancer: epigenetic stability and genome integrity
    Caporali, Sabrina
    Butera, Alessio
    Amelio, Ivano
    [J]. DISCOVER ONCOLOGY, 2022, 13 (01)
  • [8] BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
    Cigognetti, Marta
    Lonardi, Silvia
    Fisogni, Simona
    Balzarini, Piera
    Pellegrini, Vilma
    Tironi, Andrea
    Bercich, Luisa
    Bugatti, Mattia
    Rossi, Giulio
    Murer, Bruno
    Barbareschi, Mattia
    Giuliani, Silvia
    Cavazza, Alberto
    Marchetti, Gianpietro
    Vermi, William
    Facchetti, Fabio
    [J]. MODERN PATHOLOGY, 2015, 28 (08) : 1043 - 1057
  • [9] Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
    de Gooijer, Cornedine J.
    van der Noort, Vincent
    Stigt, Jos A.
    Baas, Paul
    Biesma, Bonne
    Cornelissen, Robin
    van Walree, Nico
    van Heemst, Robbert C.
    Youssef-El Soud, Magdolen
    Groen, Harry J. M.
    Staal-van den Brekel, Agnes J.
    Buikhuisen, Wieneke A.
    Bootsma, Gerben P.
    Dammeijer, Floris
    van Tinteren, Harm
    Lalezari, Ferry
    Aerts, Joachim G.
    Burgers, Jacobus A.
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (06) : 585 - 592
  • [10] Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications
    Forest, Fabien
    Patoir, Arnaud
    Dal Col, Pierre
    Sulaiman, Abdulrazzaq
    Camy, Florian
    Laville, David
    Bayle-Bleuez, Sophie
    Fournel, Pierre
    Habougit, Cyril
    [J]. PATHOLOGY, 2018, 50 (06) : 635 - 641
1234